Wainer Andrea F, a director at Neogen Corp, has reported significant stock transactions that could impact the company's executive compensation structure and shareholder perceptions. The transactions were disclosed in a recent SEC filing, reflecting Wainer's ongoing engagement with the company's equity.
Background
Neogen Corp, identified by CIK 0000711377, operates in the life sciences sector, specifically focusing on in vitro and in vivo diagnostic substances. The company is incorporated in Michigan and has its business address in Lansing. Neogen is publicly traded under the symbol NEOG.
What the Filing Says
According to the filing dated October 2, 2026, Wainer Andrea F acquired 9,804 restricted stock units at a price of $12.24 per share on October 1, 2026. Additionally, Wainer reported the acquisition of 20,558 shares of common stock, also at the price of $12.24 per share. Following these transactions, Wainer holds a total of 11,834 shares of restricted stock units and 20,558 shares of common stock.
Impact
These transactions may affect various stakeholders, including shareholders and the company's management team. The increase in Wainer's stock holdings could enhance confidence among investors regarding the company's future performance and executive commitment.
What's Next
The filing does not say what happens next.
Details of the Transactions
The filing reveals that Wainer Andrea F's acquisition of 9,804 restricted stock units and 20,558 shares of common stock was executed at a price of $12.24 per share on October 1, 2026. Notably, the common stock acquired is classified as a right to buy, which indicates that Wainer has the option to purchase these shares without any upfront cost, as the transaction price per share for the common stock was reported as $0. This right to buy has an expiration date set for October 1, 2036, providing Wainer with a long-term opportunity to benefit from any future appreciation in Neogen's stock value.
Vesting Schedule
According to the filing, both the options and restricted stock units will vest in equal annual installments over three years from the grant date. This vesting schedule aligns Wainer's interests with those of the shareholders, as it encourages a longer-term commitment to the company’s performance.
Ownership After Transactions
Post-transaction, Wainer holds a total of 11,834 shares of restricted stock units and 20,558 shares of common stock, reflecting a significant stake in Neogen Corp. This ownership structure may enhance Wainer's influence in corporate governance matters and align their interests with those of other shareholders.
Signature and Filing Details
The filing was signed by Christopher Sefcheck, acting as attorney in fact for Wainer Andrea F, on October 2, 2026. The document was submitted under SEC Form 4, which is required for reporting changes in ownership of a company's securities by its insiders.
What the Filing Does Not Include
While the filing provides detailed information about the transactions and ownership changes, it does not disclose any specific plans or intentions of Wainer Andrea F regarding future stock transactions or how these acquisitions might influence Neogen Corp's strategic direction.